{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:53:43Z","timestamp":1792047223154,"version":"4.4.0"},"reference-count":136,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease and is usually diagnosed in childhood, especially in the first decade of life. Paediatric FMF is characterized by a protean clinical expression and a variable therapeutic response, which can make its medical management very challenging. However, even if long\u2010term complications of untreated FMF (e.g. amyloidosis and related organ damage) are less frequent in children compared to adults, they are not uncommon. Colchicine is the mainstay of the therapy in paediatric FMF; however, if children develop colchicine intolerance and\/or resistance, biologics, particularly interleukin\u20101 antagonists, must be considered. Other conventional or biological therapeutic options do not currently have appropriate evidence\u2010based support, except for some specific clinical presentations (e.g., arthritis). In this review, we discuss the biological basis and the clinical evidence for the current pharmacological treatment options available for paediatric FMF.<\/jats:p>","DOI":"10.1111\/bcp.15149","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T05:48:42Z","timestamp":1637387322000},"page":"2484-2499","source":"Crossref","is-referenced-by-count":12,"title":["Conventional and novel therapeutic options in children with familial Mediterranean fever: A rare autoinflammatory disease"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-9334","authenticated-orcid":false,"given":"Dimitri","family":"Poddighe","sequence":"first","affiliation":[{"name":"Department of Medicine Nazarbayev University School of Medicine  Nur\u2010Sultan Kazakhstan"},{"name":"Clinical Academic Department of Pediatrics, National Research Center of Maternal and Child Health University Medical Center  Nur\u2010Sultan Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7823-2563","authenticated-orcid":false,"given":"Micol","family":"Romano","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine &amp; Dentistry, Department of Pediatrics, Division of Pediatric Rheumatology University of Western Ontario  London ON Canada"},{"name":"Schulich School of Medicine &amp; Dentistry, Department of Pediatrics, Canadian Behcet and Autoinflammatory Center (CAN BE AID) University of Western Ontario  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-247X","authenticated-orcid":false,"given":"Facundo","family":"Garcia\u2010Bournissen","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine &amp; Dentistry, Department of Pediatrics, Division of Pharmacology University of Western Ontario  London ON Canada"},{"name":"Schulich School of Medicine &amp; Dentistry, Department of Epidemiology and Biostatistics University of Western Ontario  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-1789","authenticated-orcid":false,"given":"Erkan","family":"Demirkaya","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine &amp; Dentistry, Department of Pediatrics, Division of Pediatric Rheumatology University of Western Ontario  London ON Canada"},{"name":"Schulich School of Medicine &amp; Dentistry, Department of Pediatrics, Canadian Behcet and Autoinflammatory Center (CAN BE AID) University of Western Ontario  London ON Canada"},{"name":"Schulich School of Medicine &amp; Dentistry, Department of Pediatrics, Division of Pharmacology University of Western Ontario  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2018.08.014"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141249"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3196-y"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0997-25"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80539-5"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07733.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01745"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000315"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key328"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0602081103"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206844"},{"key":"e_1_2_8_13_1","unstructured":"(https:\/\/infevers.umai-montpellier.fr\/web\/search.php?n=1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3715-5"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(200004)15:4<385::AID-HUMU22>3.0.CO;2-A"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163511"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215048"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218366"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216701"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666273"},{"key":"e_1_2_8_21_1","unstructured":"Center for Drug Evaluation and Research.Application number: 22\u2013351 (Summary Review). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022351s000_SumR.pdf"},{"key":"e_1_2_8_22_1","unstructured":"Center for Drug Evaluation and Research.Application number: 22\u2013352 (Summary Review). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022352s000_SumR.pdf"},{"key":"e_1_2_8_23_1","unstructured":"European Medicine Agency.EMA\/PDCO Summary Report on the review of the list of granted Class Waivers. Accessed July 1 2021.https:\/\/www.ema.europa.eu\/en\/documents\/other\/ema\/pdco-summary-report-review-list-granted-class-waivers_en.pdf"},{"key":"e_1_2_8_24_1","unstructured":"European Medicine Agency.List of nationally authorised medicinal products (Active substance: Colchicine; Procedure no.: PSUSA\/00000858\/201807). Accessed July 1 2021.https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/colchicine-list-nationally-authorised-medicinal-products-psusa\/00000858\/201807_en.pdf"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871526517666171017114901"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026613666131216110417"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/prot.20242"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.20097"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10953-010-9515-z"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0828-z"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3230189"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0171-2985(96)80027-1"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.08.006"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568010053622984"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-002-0073-2"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-1434"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463201202500429"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.05.011"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3408-9"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208690"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex222"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0980-7"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez156"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3421-8"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.05.047"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.07.010"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.03.065"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-009-1120-z"},{"issue":"24","key":"e_1_2_8_49_1","first-page":"S72","article-title":"Growth and IGF\u20101 levels of children with familial Mediterranean fever on colchicine treatment","volume":"19","author":"Kasap\u00e7opur O","year":"2001","journal-title":"Ped Rheumatol"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2006.19.2.155"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3077-9"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/OGX.0b013e318259ed3a"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201268"},{"issue":"6","key":"e_1_2_8_54_1","first-page":"97","article-title":"Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever","volume":"36","author":"Erden A","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa863"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.07.025"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001146"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3796-0"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2021.1908502"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2011.605980"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-020-05957-8"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-04237-w"},{"issue":"2","key":"e_1_2_8_63_1","first-page":"S105","article-title":"Intravenous colchicine treatment for six months: adjunctive therapy in familial Mediterranean fever (FMF) unresponsive to oral colchicine","volume":"27","author":"Rozenbaum M","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"e_1_2_8_64_1","first-page":"2620","article-title":"Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine","volume":"30","author":"Lidar M","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2010.495348"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04348-y"},{"key":"e_1_2_8_67_1","unstructured":"U.S. Food & Drug Administration (U.S. Department of Health and Human Services).COLCRYS\u2122 (colchicine USP) tablets for Oral use. (ORIG\u20101 Label). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022352lbl.pdf"},{"key":"e_1_2_8_68_1","unstructured":"U.S. Food & Drug Administration (U.S. Department of Health and Human Services).COLCRYS\u2122 (colchicine USP) tablets for Oral use (SUPPL\u20104 Label). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022352s004lbl.pdf"},{"key":"e_1_2_8_69_1","unstructured":"U.S. Food & Drug Administration (U.S. Department of Health and Human Services).COLCRYS\u2122 (colchicine USP) tablets for Oral use (SUPPL\u201014 Label). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022352s013s014lbl.pdf"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1790139"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706314"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e318277083b"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132612"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000361"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666180522085716"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.10.008"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619257"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00278"},{"key":"e_1_2_8_79_1","unstructured":"European Medicines Agency.Kineret (Annex I \u2013 Summary of product characteristics). Accessed July 1 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kineret-epar-product-information_en.pdf"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-14-40"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33342"},{"key":"e_1_2_8_82_1","unstructured":"Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research U.S. Food & Drug Administration (U.S. Department of Health and Human Services).Application number: 103950 (Medical Review). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/103950-0_Kineret_Medr.PDF"},{"key":"e_1_2_8_83_1","unstructured":"U.S. Food & Drug Administration (U.S. Department of Health and Human Services).Kineret\u00ae (anakinra) for injection for subcutaneous use (BLA 103950 SUPPL\u20105136 Label). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl.pdf"},{"key":"e_1_2_8_84_1","unstructured":"U.S. Food & Drug Administration (U.S. Department of Health and Human Services).Kineret\u00ae (anakinra) for injection for subcutaneous use (BLA 103950 SUPPL\u20105189 Label). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/103950s5189lbl.pdf"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa205"},{"key":"e_1_2_8_86_1","first-page":"75","article-title":"Efficacy of anti\u2010IL\u20101 treatment in familial Mediterranean fever: a systematic review of the literature","volume":"10","author":"Van der Hilst JC","year":"2016","journal-title":"Biol Theory"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39995"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.4774"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.987437"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13891"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa121"},{"key":"e_1_2_8_92_1","unstructured":"European Medicines Agency.Ilaris (Annex I \u2013 Summary of product characteristics). Accessed July 1 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilaris-epar-product-information_en.pdf"},{"issue":"2","key":"e_1_2_8_93_1","first-page":"397","article-title":"THU0569 Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS\/MKD and TRAPS)","volume":"75","author":"De Benedetti F","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_94_1","unstructured":"U.S. Food & Drug Administration (U.S. Department of Health and Human Services).Ilaris (canakinumab) injection for subcutaneous use (BLA 125319 SUPPL\u201085\/86\/97 Label). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/BLA125319_858687lbl.pdf"},{"key":"e_1_2_8_95_1","unstructured":"U.S. Food & Drug Administration (U.S. Department of Health and Human Services).ILARIS\u00ae (canakinumab) for injection for subcutaneous use \u2010 ILARIS\u00ae (canakinumab) injection for subcutaneous use (BLA 125319 SUPPL\u201088 Label). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125319s088lbl.pdf"},{"key":"e_1_2_8_96_1","unstructured":"U.S. Food & Drug Administration (U.S. Department of Health and Human Services).ILARIS\u00ae (canakinumab) injection for subcutaneous use (BLA 125319 SUPPL\u2010100 Label). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125319s100lbl.pdf"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38777"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00354-6"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-3993-5"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1559488"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217419"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2020.02.001"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04366-w"},{"issue":"1","key":"e_1_2_8_104_1","first-page":"1","article-title":"Retrospective case series describing the efficacy, safety and cost\u2010effectiveness of a vial\u2010sharing programme for canakinumab treatment for paediatric patients with cryopyrin\u2010associated periodic syndrome","volume":"17","author":"Elmi AA","year":"2019","journal-title":"Ped Rheumatol"},{"key":"e_1_2_8_105_1","unstructured":"Regeneron Pharmaceuticals I. Investigator's Brochure. Accessed July 1 2021.https:\/\/investor.regeneron.com\/static-files\/a7704757-12af-48fc-be5f-6788f9498822"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.372"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1313116"},{"key":"e_1_2_8_108_1","unstructured":"Center for Drug Evaluation and Research.Application number: 125259 (Summary Review). Accessed July 1 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/125249s000_MedR.pdf"},{"key":"e_1_2_8_109_1","unstructured":"European Medicine Agency.EU\/3\/07\/456: Rilonacept. Accessed July 1 2021.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu307456"},{"key":"e_1_2_8_110_1","unstructured":"European Medicine Agency. Rilonacept Regeneron (Rilonacept).Withdrawal of the marketing authorisation in the European Union. Accessed July 1 2021.https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-rilonacept-regeneron-withdrawal-marketing-authorisation-european-union_en.pdf"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-8-201210160-00003"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/854842"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3293-2"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100718"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1709258"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-008-0875-y"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000770"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2020.02.002"},{"issue":"4","key":"e_1_2_8_119_1","first-page":"S77","article-title":"Therapeutic approach to familial Mediterranean fever: a review update","volume":"29","author":"Ozturk MA","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.10.004"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4163-5"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0642-0"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.908810"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1709258"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-3105-6"},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018328"},{"key":"e_1_2_8_127_1","unstructured":"Randomized double\u2010blind parallel group comparison trial of Tocilizumab for colchicine\u2010resistant familial Mediterranean fever (UMIN000028010). In: UMIN\u2010CTR Clinical Trial Website. Accessed October 16 2021. URL:https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000032030"},{"key":"e_1_2_8_128_1","unstructured":"An open\u2010label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance (UMIN000032557). In: UMIN\u2010CTR Clinical Trial Website. Accessed October 16 2021. URL:https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000037116"},{"key":"e_1_2_8_129_1","unstructured":"Tocilizumab for the Treatment of Familial Mediterranean Fever (NCT03446209). In:ClinicalTrials.gov. Accessed October 16 2021. URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03446209"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04490-7"},{"issue":"1","key":"e_1_2_8_131_1","first-page":"88","article-title":"Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever","volume":"42","author":"G\u00f6k K","year":"2017","journal-title":"Acta Reumatol Port"},{"key":"e_1_2_8_132_1","unstructured":"U.S. FOOD & DRUG ADMINISTRATION.FDA requires warnings about increased risk of serious heart\u2010related events cancer blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions. Accessed October 16 2021. URL:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-anddeath#:~:text=FDA%20is%20requiring%20new%20and treat%20certain%20 serious%20inflammatory%20conditions"},{"key":"e_1_2_8_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04892-6"},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04809-3"},{"key":"e_1_2_8_135_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666151117121706"},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.002"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab577"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15149","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15149","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T21:51:34Z","timestamp":1692827494000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":136,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/bcp.15149"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15149","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]}}}